|
|
Background: The aim was to evaluate serum levels of Phosphoserine Phosphatase (PSPH) and Chemokine C-X-C Motif Ligand 2 (CXCL2) as biomarkers for predicting antipsychotic treatment response in male first-episode schizophrenia patients.
Methods: Bioinformatics analysis identified upregulated PSPH and CXCL2 expression in PBMCs of schizophrenia patients. Clinical data from 297 male patients (treated with olanzapine from 2019 to 2024) were retrospectively analyzed. After 4 weeks, patients were categorized into improvement (n = 118) and non-improvement (n = 179) groups. Serum PSPH and CXCL2 levels were measured by ELISA. Predictive value was assessed via ROC and multivariate logistic regression.
Results: The non-improvement group had higher PSPH/CXCL2 levels. Both biomarkers correlated positively with PANSS scores (r = 0.249, 0.335; p < 0.001). Logistic regression confirmed PSPH/CXCL2 levels, pre-treatment PANSS, shorter disease duration, and younger age as independent predictors (p < 0.05). Combined PSPH/CXCL2 showed superior predictive performance (AUC = 0.823, p < 0.05).
Conclusions: Serum levels of PSPH and CXCL2 can be considered as potential biomarkers for predicting the efficacy of antipsychotic treatment in male patients with first-episode schizophrenia.
DOI: 10.7754/Clin.Lab.2025.250683
|
